BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million.Read More
BioTime (NYSE MKT, TASE:BTX) has closed a public offering of 7,453,704 common shares, including 972,222 shares in connection with the exercise in full of an underwriters’ over allotment option, at a price of $2.70 a share for gross proceeds of about $20.1-million.Read More
Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300 shares.Read More
GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of 9,794,203 units, at a price of 16 cents each, for proceeds of about $1.6-million.
Each unit consists of one common share and one-quarter of a warrant. Each whole warrant entitles the holder to acquire one common share at a price of 50 cents until August 15, 2018.Read More
Atossa Genetics (NASDAQ:ATOS) has priced a public offering of 1,150,000 common shares at a price of $2.50 a share for gross proceeds of about $2,875,000.
Atossa Genetics also granted underwriters a 45-day option to purchase up to an additional 172,500 shares to cover over-allotments. The offering is expected to close on Sept. 6.Read More
Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada.
Under the accord, Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.Read More
Leerink downgraded Imprivata (NYSE:IMPR) to “market perform” but upped its price target to $19.25 from $17 after the company entered into a definitive agreement to be acquired by an affiliate of Thoma Bravo, LLC, a private equity investment firm. The stock closed at $19.01 on Wednesday.
Shareholders will receive $19.25 in cash per share of Imprivata common stock, which is a 33% premium to Tuesday’s closing price of $14.50.Read More
Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.
Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.Read More